SCHEMBL29954084

SCHEMBL29954084

OB(O)c1ccc(Cl)cc1O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 5/20 0.52
ALDH1A1 P00352 4/20 0.52
TSHR P16473 4/20 0.52
CYP3A4 P08684 3/20 0.52
TDP1 Q9NUW8 1/20 0.52
HPGD P15428 5/20 0.45
HSP90AA1 P07900 4/20 0.45
MAPT P10636 3/20 0.45
LMNA P02545 2/20 0.45
HSPA5 P11021 2/20 0.45
NR1I2 O75469 1/20 0.45
TTR P02766 1/20 0.45
PGR P06401 1/20 0.45
ADORA3 P0DMS8 1/20 0.45
CBR1 P16152 1/20 0.45
TBXA2R P21731 1/20 0.45
SLC6A2 P23975 1/20 0.45
AGTR1 P30556 1/20 0.45
SLC6A3 Q01959 1/20 0.45
ERN1 O75460 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2587772 1.00 HSD17B10 (0.52) HSD17B10ALDH1A1TSHRCYP3A4TDP1
SCHEMBL320185 0.81 HSD17B10 (0.52) HSD17B10ALDH1A1TSHRCYP3A4TDP1
SCHEMBL31112067 0.81 HSD17B10 (0.52) HSD17B10ALDH1A1TSHRCYP3A4TDP1
SCHEMBL29375771 0.78 TSHR (0.48) HSD17B10ALDH1A1TSHRCYP3A4TDP1
SCHEMBL41990 0.78 TSHR (0.48) HSD17B10ALDH1A1TSHRCYP3A4TDP1
SCHEMBL25365977 0.77 CYP2A6 (0.43) HSD17B10ALDH1A1TSHRCYP3A4TDP1
SCHEMBL25363704 0.77 CYP2A6 (0.43) HSD17B10ALDH1A1TSHRCYP3A4TDP1
SCHEMBL25459961 0.77 HPGD (0.40) HSD17B10ALDH1A1TSHRCYP3A4TDP1
SCHEMBL624402 0.76 CYP3A4 (0.43) HSD17B10ALDH1A1TSHRCYP3A4TDP1
SCHEMBL29825793 0.76 CYP3A4 (0.43) HSD17B10ALDH1A1TSHRCYP3A4TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4347571-B1 TRIAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER. HOFFMANN LA ROCHE (CH) 2026-04-22 EP disclosed
EP-4504733-A1 FUSED PYRIDAZINE DERIVATIVES AS NLRP3 INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2025-02-12 EP disclosed
EP-4499638-A1 PYRIDO-[3,4-D]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 DERIVATIVES Ventus Therapeutics U.S., Inc. (US) 2025-02-05 EP disclosed
EP-4347571-A1 TRIAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER F. Hoffmann-La Roche AG (CH) 2024-04-10 EP disclosed
WO-2023183943-A1 PYRIDO-[3,4-D]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 DERIVATIVES VENTUS THERAPEUTICS U.S., INC. (US) 2023-09-28 WO disclosed
WO-2022253936-A1 TRIAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER. F. HOFFMANN-LA ROCHE AG (CH) 2022-12-08 WO disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed